We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00273000
Recruitment Status : Unknown
Verified October 2005 by Glostrup University Hospital, Copenhagen.
Recruitment status was:  Recruiting
First Posted : January 9, 2006
Last Update Posted : September 11, 2006
Sponsor:
Collaborators:
Rigshospitalet, Denmark
University of Copenhagen
Information provided by:
Glostrup University Hospital, Copenhagen

Brief Summary:
The purpose of this study is to study the effect of GLP-2 on mesenteric bloodflow in healthy adults by the use of ultrasound., it is the hypothesis that GLP-2 vil increase the bloodflow.

Condition or disease Intervention/treatment
Healthy Drug: GLP-2

Detailed Description:

The investigation will include 10 testpersons.

It will be a 2 fase study over 2 days.

day 1: The testperson will meet fasting, and take in a standard liquid meal, after this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.

day 2:The testperson will meet fasting, there wil be administered intraveneous GLP-2 in 3 increasing doses over 3 x 45 min.and one subcutaneous dose. During this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans
Study Start Date : January 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Glucagon
U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy

Exclusion Criteria:

  • use of drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273000


Contacts
Contact: Lasse Bremholm Hansen, MD 004560927874 hoersted-bremholm@webspeed.dk

Locations
Denmark
Rigshospitalet Recruiting
Copenhagen, Copenhagen City, Denmark, 2100
Contact: Lasse Bremholm Hansen, MD    004560927874    hoersted-bremholm@webspeed.dk   
Sub-Investigator: Mads Hornum, MD         
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
Rigshospitalet, Denmark
University of Copenhagen
Investigators
Principal Investigator: Mads Hornum, MD Glostrup University Hospital, Copenhagen

ClinicalTrials.gov Identifier: NCT00273000     History of Changes
Other Study ID Numbers: GLP-2, MBF
First Posted: January 9, 2006    Key Record Dates
Last Update Posted: September 11, 2006
Last Verified: October 2005

Additional relevant MeSH terms:
Glucagon
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Incretins